Drug Trial Radar · NCT05024214
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Nov 15, 2021
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- 3D Medicines (Sichuan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors. The primary hypothesis of this study is that subjects will have a better objective response rate (ORR) when treated with Envafolimab plus Lenvatinib than SOC.
Conditions
- Solid Tumors
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
Interventions
Lenvatinib + EnvafolimabDrug
Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle. Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.
SunitinibDrug
Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RP2D(Phase Ib)Time frame: first Cycle (28 Days)
- Dose Limiting Toxicity (DLT) (Phase Ib)Time frame: first Cycle (28 Days)
- objective response rate (ORR) (Phase II)Time frame: Two years
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Fudan University
Shanghai, China · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Recruiting
The Seventh Medical Center of the PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Not yet recruiting
Zhongshan Hospital,Fudan University(Xiamen Branch)
Xiamen, Fujian, China · Not yet recruiting
Dongguan People's Hospital
Dongguan, Guangdong, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
The Fifth Affiliated Hospital Sun Yat-Sen University
Zhuhai, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Haerbin, Heilongjiang, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
The Second Affiliater Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
THE First Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Recruiting
The 960th Hospital of the PLA Joint Logistics Support Force
Jinan, Shandong, China · Recruiting
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The Cancer Affiliated Hospital of Xinjiang Medical College
Ürümqi, Xinjiang, China · Recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Recruiting
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.